These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

187 related items for PubMed ID: 15063428

  • 1. Decreased circulating Fas ligand in patients with familial combined hyperlipidemia or carotid atherosclerosis: normalization by atorvastatin.
    Blanco-Colio LM, Martín-Ventura JL, Sol JM, Díaz C, Hernández G, Egido J.
    J Am Coll Cardiol; 2004 Apr 07; 43(7):1188-94. PubMed ID: 15063428
    [Abstract] [Full Text] [Related]

  • 2. One-year atorvastatin treatment in hypercholesterolemic patients with or without carotid artery disease.
    Avellone G, Di Garbo V, Abruzzese G, Campisi D, De Simone R, Raneli G, Licata G.
    Int Angiol; 2006 Mar 07; 25(1):26-34. PubMed ID: 16520721
    [Abstract] [Full Text] [Related]

  • 3. The effect of apolipoprotein E polymorphism on the response to lipid-lowering treatment with atorvastatin or fenofibrate.
    Christidis DS, Liberopoulos EN, Kakafika AI, Miltiadous GA, Cariolou M, Ganotakis ES, Mikhailidis DP, Elisaf MS.
    J Cardiovasc Pharmacol Ther; 2006 Sep 07; 11(3):211-21. PubMed ID: 17056835
    [Abstract] [Full Text] [Related]

  • 4. Atorvastatin monotherapy vs. combination therapy in the management of patients with combined hyperlipidemia.
    Avisar I, Brook JG, Wolfovitz E.
    Eur J Intern Med; 2008 May 07; 19(3):203-8. PubMed ID: 18395165
    [Abstract] [Full Text] [Related]

  • 5. 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors decrease Fas ligand expression and cytotoxicity in activated human T lymphocytes.
    Blanco-Colio LM, Muñoz-García B, Martín-Ventura JL, Lorz C, Díaz C, Hernández G, Egido J.
    Circulation; 2003 Sep 23; 108(12):1506-13. PubMed ID: 12952848
    [Abstract] [Full Text] [Related]

  • 6. Effect of statins on LDL particle size in patients with familial combined hyperlipidemia: a comparison between atorvastatin and pravastatin.
    Sirtori CR, Calabresi L, Pisciotta L, Cattin L, Pauciullo P, Montagnani M, Manzato E, Bittolo Bon G, Fellin R.
    Nutr Metab Cardiovasc Dis; 2005 Feb 23; 15(1):47-55. PubMed ID: 15871851
    [Abstract] [Full Text] [Related]

  • 7. Clinical outcomes in managed-care patients with coronary heart disease treated aggressively in lipid-lowering disease management clinics: the alliance study.
    Koren MJ, Hunninghake DB, ALLIANCE Investigators.
    J Am Coll Cardiol; 2004 Nov 02; 44(9):1772-9. PubMed ID: 15519006
    [Abstract] [Full Text] [Related]

  • 8. A 52-week, randomized, open-label, parallel-group comparison of the tolerability and effects of pitavastatin and atorvastatin on high-density lipoprotein cholesterol levels and glucose metabolism in Japanese patients with elevated levels of low-density lipoprotein cholesterol and glucose intolerance.
    Sasaki J, Ikeda Y, Kuribayashi T, Kajiwara K, Biro S, Yamamoto K, Ageta M, Kobori S, Saikawa T, Otonari T, Kono S.
    Clin Ther; 2008 Jun 02; 30(6):1089-101. PubMed ID: 18640465
    [Abstract] [Full Text] [Related]

  • 9. Increased plasma levels of oxysterols, in vivo markers of oxidative stress, in patients with familial combined hyperlipidemia: reduction during atorvastatin and fenofibrate therapy.
    Arca M, Natoli S, Micheletta F, Riggi S, Di Angelantonio E, Montali A, Antonini TM, Antonini R, Diczfalusy U, Iuliano L.
    Free Radic Biol Med; 2007 Mar 01; 42(5):698-705. PubMed ID: 17291993
    [Abstract] [Full Text] [Related]

  • 10. Effect of atorvastatin on circulating proinflammatory T-lymphocyte subsets and soluble CD40 ligand in patients with stable coronary artery disease--a randomized, placebo-controlled study.
    Alber HF, Frick M, Suessenbacher A, Doerler J, Schirmer M, Stocker EM, Dichtl W, Pachinger O, Weidinger F.
    Am Heart J; 2006 Jan 01; 151(1):139. PubMed ID: 16368305
    [Abstract] [Full Text] [Related]

  • 11. Comparison of atorvastatin versus fenofibrate in reaching lipid targets and influencing biomarkers of endothelial damage in patients with familial combined hyperlipidemia.
    Arca M, Montali A, Pigna G, Antonini R, Antonini TM, Luigi P, Fraioli A, Mastrantoni M, Maddaloni M, Letizia C.
    Metabolism; 2007 Nov 01; 56(11):1534-41. PubMed ID: 17950105
    [Abstract] [Full Text] [Related]

  • 12. Effects of rosiglitazone alone and in combination with atorvastatin on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus.
    Chu CS, Lee KT, Lee MY, Su HM, Voon WC, Sheu SH, Lai WT.
    Am J Cardiol; 2006 Mar 01; 97(5):646-50. PubMed ID: 16490430
    [Abstract] [Full Text] [Related]

  • 13. Efficacy and safety of combination of extended release niacin and atorvastatin in patients with low levels of high density lipoprotein cholesterol.
    Harikrishnan S, Rajeev E, Tharakan JA, Titus T, Ajit Kumar VK, Sivasankaran S, Krishnamoorthy KM, Nair K.
    Indian Heart J; 2008 Mar 01; 60(3):215-22. PubMed ID: 19240310
    [Abstract] [Full Text] [Related]

  • 14. Fas ligand mRNA levels of circulating leukocytes reflect endothelial dysfunction in hyperlipidemic but not in non-hyperlipidemic patients.
    Kotani N, Fukuo K, Yasuda O, Sugimoto K, Katuya T, Takemura Y, Kawamoto H, Yokoi T, Suzuki A, Ogihara T.
    Hypertens Res; 2006 Apr 01; 29(4):217-25. PubMed ID: 16778328
    [Abstract] [Full Text] [Related]

  • 15. Increased soluble Fas plasma levels in subjects at high cardiovascular risk: Atorvastatin on Inflammatory Markers (AIM) study, a substudy of ACTFAST.
    Blanco-Colio LM, Martín-Ventura JL, de Teresa E, Farsang C, Gaw A, Gensini G, Leiter LA, Langer A, Martineau P, Hérnandez G, Egido J, ACTFAST investigators.
    Arterioscler Thromb Vasc Biol; 2007 Jan 01; 27(1):168-74. PubMed ID: 17053166
    [Abstract] [Full Text] [Related]

  • 16. Qualitative effect of fenofibrate and quantitative effect of atorvastatin on LDL profile in combined hyperlipidemia with dense LDL.
    Winkler K, Weltzien P, Friedrich I, Schmitz H, Nickell HH, Hauck P, Hoffmann MM, Baumstark MW, Wieland H, März W.
    Exp Clin Endocrinol Diabetes; 2004 May 01; 112(5):241-7. PubMed ID: 15146369
    [Abstract] [Full Text] [Related]

  • 17. The DISCOVERY PENTA study: a DIrect Statin COmparison of LDL-C Value--an Evaluation of Rosuvastatin therapY compared with atorvastatin.
    Fonseca FA, Ruiz A, Cardona-Muñoz EG, Silva JM, Fuenmayor N, Marotti M, DISCOVERY PENTA investigators.
    Curr Med Res Opin; 2005 Aug 01; 21(8):1307-15. PubMed ID: 16083541
    [Abstract] [Full Text] [Related]

  • 18. Adiponectin plasma levels are increased by atorvastatin treatment in subjects at high cardiovascular risk.
    Blanco-Colio LM, Martín-Ventura JL, Gómez-Guerrero C, Masramon X, de Teresa E, Farsang C, Gaw A, Gensini G, Leiter LA, Langer A, Egido J.
    Eur J Pharmacol; 2008 May 31; 586(1-3):259-65. PubMed ID: 18374327
    [Abstract] [Full Text] [Related]

  • 19. Effect of lowering LDL cholesterol substantially below currently recommended levels in patients with coronary heart disease and diabetes: the Treating to New Targets (TNT) study.
    Shepherd J, Barter P, Carmena R, Deedwania P, Fruchart JC, Haffner S, Hsia J, Breazna A, LaRosa J, Grundy S, Waters D.
    Diabetes Care; 2006 Jun 31; 29(6):1220-6. PubMed ID: 16731999
    [Abstract] [Full Text] [Related]

  • 20. Effect of low doses of atorvastatin on adiponectin, glucose homeostasis, and clinical inflammatory markers in kidney transplant recipients.
    Bayés B, Granada ML, Lauzurica R, Pastor MC, Navarro M, Bonet J, Llopis MA, Romero R.
    Transplant Proc; 2005 Nov 31; 37(9):3808-12. PubMed ID: 16386546
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.